The A4 Study: Stopping AD Before Symptoms Begin?

Reisa A. Sperling; Dorene M. Rentz; Keith A. Johnson; Jason Karlawish; Michael Donohue; David P. Salmon; Paul Aisen

doi:10.1126/scitranslmed.3007941

Skip to main content

ScienceMag.org

Search

Read our COVID-19 research and news.

You are currently viewing the abstract.

View Full Text

Log in to view the full text

via AAAS login

AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in through your institution

More options

Purchase digital access to this article

Download and print this article for your personal scholarly, research, and educational use.

Purchase this issue in print

Buy a single issue of Science for just $15 USD.

Abstract

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Copyright © 2014, American Association for the Advancement of Science

View Full Text

Science Translational Medicine

Vol 6, Issue 228
19 March 2014

Table of Contents

Article Tools

Email

Thank you for your interest in spreading the word about Science Translational Medicine.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email

Your Name

Send To
Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The A4 Study: Stopping AD Before Symptoms Begin?

Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

Your Personal Message

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Powerpoint
Print
Alerts

Please log in to add an alert for this article.

Log In with your AAAS ID

Sign In to Email Alerts with your Email Address
Email
Citation tools
The A4 Study: Stopping AD Before Symptoms Begin?

By Reisa A. Sperling, Dorene M. Rentz, Keith A. Johnson, Jason Karlawish, Michael Donohue, David P. Salmon, Paul Aisen

Science Translational Medicine19 Mar 2014 : 228fs13

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Citation Manager Formats

BibTeX

Bookends

EasyBib

EndNote (tagged)

EndNote 8 (xml)

Medlars

Mendeley

Papers

RefWorks Tagged

Ref Manager

RIS

Zotero
Share

The A4 Study: Stopping AD Before Symptoms Begin?

By Reisa A. Sperling, Dorene M. Rentz, Keith A. Johnson, Jason Karlawish, Michael Donohue, David P. Salmon, Paul Aisen

Science Translational Medicine19 Mar 2014 : 228fs13

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Share This Article: